Featured Research

from universities, journals, and other organizations

Long-term Etanercept Treatment Reduces Psoriasis Severity Without Increased Adverse Events

Date:
June 20, 2007
Source:
JAMA and Archives Journals
Summary:
Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a recent article.

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a recent article.

Related Articles


Psoriasis, a chronic inflammatory skin disorder, usually requires long-term therapy, according to background information in the article. "Serum and affected tissue levels of tumor necrosis factor (TNF) are elevated in patients with psoriasis compared with levels in uninvolved skin of patients with psoriasis and in healthy individuals, suggesting that TNF plays an important role in the pathogenesis of the disease," the authors write. Etanercept, which binds with TNF, has been approved to treat several inflammatory diseases, including psoriasis.

Stephen Tyring, M.D., Ph.D., The University of Texas Health Science Center at Houston, and colleagues conducted a phase 3 randomized, double-blind trial with an open-label extension (during which all patients were aware that they were taking the active drug) from May 23, 2003, through June 22, 2005.

After a 12-week period during which 618 patients with moderate to severe psoriasis were randomly assigned to receive either placebo or 50 milligrams of etanercept twice weekly (the current recommended dosage for psoriasis) for 12 weeks, all 591 continuing patients (average age 45.7) received etanercept for up to 84 weeks. During this open-label period, safety and efficacy evaluations were completed every 12 weeks. Psoriasis severity was measured using the Psoriasis Area and Severity Index (PASI) score, where zero means no disease and 72 is the most severe disease.

"Exposure-adjusted rates of adverse events, serious adverse events, infections and serious infections were similar for placebo and etanercept treatments," the authors write. "Patients responded within two weeks to etanercept, with statistically significant differences in the Psoriasis Area and Severity Index and Dermatology Life Quality Index between the etanercept and placebo groups at week 12. At week 24, after 12 weeks of open-label etanercept treatment, patients in the original placebo group had clinical benefits comparable to those of patients in the original etanercept group."

Improvements in PASI scores peaked at week 48, and at the end of the study, 51.6 percent of the original placebo group and 51.1 percent of the original etanercept group improved by at least 75 percent. A total of 18.3 percent of patients developed antibodies to etanercept during the study, but these antibodies did not appear to cause adverse events or reduce the drug's effectiveness.

"In conclusion, this study represents, to our knowledge, the longest continuous exposure of patients with psoriasis to 50 milligrams of etanercept biweekly and provides further insights into the safety and efficacy of high-dose etanercept therapy for the management of moderate to severe psoriasis," the authors conclude.

Reference: Arch Dermatol. 2007;143:719-726.

This study was supported by Immunex Corporation, a wholly owned subsidiary of Amgen Inc, and by Wyeth Pharmaceuticals.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Long-term Etanercept Treatment Reduces Psoriasis Severity Without Increased Adverse Events." ScienceDaily. ScienceDaily, 20 June 2007. <www.sciencedaily.com/releases/2007/06/070618164133.htm>.
JAMA and Archives Journals. (2007, June 20). Long-term Etanercept Treatment Reduces Psoriasis Severity Without Increased Adverse Events. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2007/06/070618164133.htm
JAMA and Archives Journals. "Long-term Etanercept Treatment Reduces Psoriasis Severity Without Increased Adverse Events." ScienceDaily. www.sciencedaily.com/releases/2007/06/070618164133.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins